Trastuzumab Therapy and the Heart: Palliation at What Cost?
نویسندگان
چکیده
منابع مشابه
A Glance at the Cost of Chelation Therapy with Desferal and Exjade in Iran
Background: Thalassemia is a series of hemoglobinopathies in which the production of perfect hemoglobin is completely or partially suppressed. Using injectable iron chelators have been dominating treatment for the iron overload caused by recurrent blood transfusions in thalassemic patients, however, a new oral iron chelating drug (Exjade) have been recently introduced and might be cost effec...
متن کاملGME: at what cost?
Current computing methods impede determining the real cost of graduate medical education. However, a more accurate estimate could be obtained if policy makers would allow for the application of basic cost-accounting principles, including consideration of department-level costs, unbundling of joint costs, and other factors.
متن کاملTrastuzumab-induced cardiotoxicity: heart failure at the crossroads.
Trastuzumab, a drug targeting human epidermal growth factor receptor 2, improves survival rate in women with metastatic breast cancer. Symptomatic heart failure, a serious adverse effect of trastuzumab, occurs in 1% to 4% of patients treated with the antibody, whereas left ventricular ejection fraction declines substantially in 10% of patients. The prevalence of cardiotoxic effects of trastuzum...
متن کاملScalability! But at what COST?
We offer a new metric for big data platforms, COST, or the Configuration that Outperforms a Single Thread. The COST of a given platform for a given problem is the hardware configuration required before the platform outperforms a competent single-threaded implementation. COST weighs a system’s scalability against the overheads introduced by the system, and indicates the actual performance gains ...
متن کاملTrastuzumab and congestive heart failure: what can we learn from use in the community?
The development of trastuzumab for the treatment of non–meta-static invasive breast cancer tumors expressing HER2 has been lauded as an " elegant example of translational research " (1), representing an important step toward the " era of personalized oncology " (2). Multiple trials have documented clinically and statistically significant improvements in overall and disease-free survival for wom...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Congestive Heart Failure
سال: 2001
ISSN: 1527-5299,1751-7133
DOI: 10.1111/j.1527-5299.2001.00241.x